NVS

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

China Automotive Infrared Night Vision System Research Report 2023 - OEMs Begin to Integrate ADAS with Infrared Night Vision Technology

Retrieved on: 
Friday, February 16, 2024
Aion, BEV, WeRide, Radar, Temperature, Miniaturization, Aion Hyper GT, ADAS, SLAM, Lidar, Thanu Nenu, Night vision, Perception, PLCC, Safety, BMW, History, GAC, SXGA, NVS, Software, Telescopic sight

DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Automotive Infrared Night Vision System Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Automotive Infrared Night Vision System Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • During 2022-2023, the installations of NVS (night vision system) in new passenger cars in China went up at first and then down.
  • Active infrared night vision is also called near-infrared night vision; passive infrared night vision falls into far-infrared night vision and low-light-level night vision.
  • In July 2023, Aion Hyper GT, an ADAS-enabled production model integrated with infrared night vision technology, was available on market.

China Automotive Infrared Night Vision System Research Report 2023: Infrared Detector Heads in the Direction of Small Pixel Size and Low Cost - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 15, 2024
Vehicle Technology, Automotive, Technology, Transport, Other Technology, Other Transport, Aion, BEV, WeRide, Radar, Temperature, Miniaturization, Aion Hyper GT, ADAS, SLAM, Lidar, Thanu Nenu, Night vision, Perception, PLCC, Safety, BMW, History, GAC, SXGA, NVS, Software, Telescopic sight

The "Automotive Infrared Night Vision System Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Automotive Infrared Night Vision System Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • Active infrared night vision is also called near-infrared night vision; passive infrared night vision falls into far-infrared night vision and low-light-level night vision.
  • Infrared detector, an important upstream product in the industry chain, heads in the direction of small pixel size and low cost.
  • Wherein, the infrared detector, also known as infrared focal plane detector, is an important part of a far-infrared night vision system, and is heading in the direction of small pixel size and low cost.

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Retrieved on: 
Wednesday, February 14, 2024
NRAS, NSCLC, SAN, Lung cancer, Patient, Mutation, Pancreatic cancer, Thyroid cancer, Colorectal cancer, NVS, MEK, Cancer, Melanoma, Pharmaceutical industry

SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced two clinical trial collaboration and supply agreements (CTCSAs) with Novartis (NYSE: NVS) for the MEK inhibitor trametinib (MEKINIST®).

Key Points: 
  • Erasca is sponsoring the trials, and Novartis is supplying trametinib at no cost.
  • “Both trials are supported by compelling anti-tumor activity with a tolerable and manageable adverse event profile demonstrated in clinical data generated by Novartis.
  • Both RAS Q61X solid tumors and NRASm melanoma represent high unmet needs with no approved targeted therapies for these respective mutation types.
  • Erasca is exploring whether naporafenib in combination with trametinib can improve outcomes and help provide meaningful therapeutic benefit for these advanced solid tumor indications.

EQS-News: Netfonds: Strategic acquisition to further develop the insurance division and strengthen profitability

Retrieved on: 
Tuesday, January 30, 2024
MFK, NVS, CFO, Partnership, Insurance, Consultant, Acquisition, IGBCE, Management

January 2024 - Netfonds (ISIN: DE000A1MME74) strengthens its insurance division by acquiring a majority stake in Meine Finanzkanzlei GmbH (MFK), Lengerich.

Key Points: 
  • January 2024 - Netfonds (ISIN: DE000A1MME74) strengthens its insurance division by acquiring a majority stake in Meine Finanzkanzlei GmbH (MFK), Lengerich.
  • Netfonds acquired the strategic majority stake through its fully owned subsidiary NVS Netfonds Versicherungsservice AG (NVS).
  • "The acquisition of shares in MFK will immediately strengthen the profitability of our insurance division and, in particular, boost our service subsidiary NVS," says Peer Reichelt, CFO of Netfonds AG.
  • The acquisition of shares in MFK represents an important step in the strategic development of Netfonds Versicherungsservice AG.

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

Retrieved on: 
Tuesday, January 2, 2024
Spinal muscular atrophy, NVS, HD, Therapy, TRACER, DSM-IV codes, Biomedical Research, Biomedicine, Central nervous system, Patient, SMA, Pharmaceutical industry

LEXINGTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER™ capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.

Key Points: 
  • LEXINGTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
  • Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER™ capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.
  • “We are thrilled to expand our existing relationship with Novartis, a global leader in the gene therapy field,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager.
  • Novartis will also receive worldwide rights to Voyager’s AAV gene therapy for HD, leveraging Voyager’s TRACER capsids and proprietary payloads.

OTC Markets Group Welcomes Sandoz Group AG to OTCQX

Retrieved on: 
Wednesday, October 4, 2023
NVS, SIX Swiss Exchange, Patient, SDZ, OTCQX, NYSE, J. P. Morgan, Security (finance), Novartis

NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Sandoz Group AG (SIX Swiss Exchange: SDZ; OTCQX: SDZNY, SDZXF), a global leader in generic pharmaceuticals and biosimilars, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Sandoz Group AG (SIX Swiss Exchange: SDZ; OTCQX: SDZNY, SDZXF), a global leader in generic pharmaceuticals and biosimilars, has qualified to trade on the OTCQX® Best Market.
  • Sandoz Group AG begins trading today on OTCQX under the symbols “SDZNY, SDZXF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets.
  • And we intend to make an even greater impact going forward.”
    J.P. Morgan acted as the company’s OTCQX sponsor.

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

Retrieved on: 
Wednesday, September 13, 2023
China Biologic Products, IBN, Injection, Plaque, Asthma, NVS, Therapy, Dermis, AMD, University Medical Center, Hook effect, I&I, 3D, European Medicines Agency, COVID-19, Clinical trial, Infection, Inflammation, IL-17A, Psoriasis, EMA, VHH, LLY, UCB, Novartis, Patient, Lilly, Risk, Max Planck Institute for Multidisciplinary Sciences, Brussels Stock Exchange, UMG, Mab, CCL20, CXCL1, AF, Research, Moonlake, NYSE, Max Planck Society, Skin, Autoimmunity, Disease, Pharmaceutical industry, Vaccine

JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.

Key Points: 
  • Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-vivo animal study results anticipated in early 2024
    JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.
  • These results suggest NanoAbs’ therapeutic potential to relieve symptoms of plaque psoriasis.
  • Research shows that targeting IL-17F isoform in addition to IL-17A provides higher efficacy in treating plaque psoriasis.
  • Scinai recently started to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for plaque psoriasis to evaluate the effective dose and schedule of treatment, with in-vivo animal studies anticipated in early 2024.

NIKE Announces Senior Leadership Changes to Deepen Consumer-Led Growth and Marketplace Advantage

Retrieved on: 
Wednesday, May 24, 2023
Textiles, Department Stores, Sports, General Sports, Other Retail, Manufacturing, Fashion, Retail, Footwear, Online Retail, Air Jordan, NVS, Campion, Nike, Service, Culture, EVP, Multimedia, Marketing, Athlete, Direct, GM, Converse, NKE, Consumer, Growth, NYSE, Procurement, Management

Aligning against its next chapter of growth, O’Neill will lead Nike’s global product engine and fully integrate its brand marketing storytelling to build deep relationships and engagement with the brand.

Key Points: 
  • Aligning against its next chapter of growth, O’Neill will lead Nike’s global product engine and fully integrate its brand marketing storytelling to build deep relationships and engagement with the brand.
  • A 24-year Nike veteran, O’Neill most recently served as Nike’s President, Consumer & Marketplace, leading Nike’s marketplace and four geographic operating regions.
  • Andy Campion, Chief Operating Officer, will take on a new leadership role as Managing Director, Strategic Business Ventures.
  • Michael Spillane, President, Consumer Creation will retire from NIKE, Inc. later in 2023 after 16 years with the company.